CYTH היקף נכסי החברה CTD Holdings

Cyclo Therapeutics (CYTH) relies on outsourcing production and trials to avoid capital expenditures on manufacturing plants. This chart reflects an asset value of 5.43, visualizing total assets. Market capitalization growth is driven by Trappsol Cyclo's success in treating Niemann-Pick disease and support from the Rafael fund, as well as the implementation of software robots for big data analysis and the automation of molecule screening.

For Cyclo Therapeutics, the trend in total assets directly reflects the scale of investment in the development of Trappsol Cyclo, where resource growth—calculated via assets and resources and reverse-engineered through ROA—signals an expanding base for the completion of clinical trials. The increase in total asset value confirms readiness to monetize the orphan market, although investors must distinguish organic growth from excessive debt load.